Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Long-Term Deferred Tax (2017 - 2024)

Dianthus Therapeutics has reported Long-Term Deferred Tax over the past 2 years, most recently at $21.7 million for Q4 2024.

  • Quarterly results put Long-Term Deferred Tax at $21.7 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $21.7 million (changed N/A YoY), and the annual figure for FY2024 was $21.7 million, changed.
  • Long-Term Deferred Tax for Q4 2024 was $21.7 million at Dianthus Therapeutics, up from $12.5 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for DNTH hit a ceiling of $21.7 million in Q4 2024 and a floor of $21.7 million in Q4 2024.